TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Phase 2

Active, not recruiting

• Conditions: Recurrent Colon Carcinoma; Metastatic Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colon Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7
• Interventions: Drug: Oxaliplatin; Drug: Trifluridine and Tipiracil Hydrochloride

• Registration Number: NCT04294264
• Lead Sponsor: Rutgers, The State University of New Jersey

Brief Summary

This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Detailed Description

PRIMARY OBJECTIVE:

I. Overall response rate (ORR).

SECONDARY OBJECTIVES:

I. Progression free survival (PFS). II. Overall survival (OS). III. Disease control rate (DCR). IV. Duration of response. V. Safety and tolerability.

OUTLINE:

Patients receive trifluridine and tipiracil hydrochloride (TAS-102) orally (PO) twice daily (BID) on days 1-5 and oxaliplatin intravenously (IV) over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days.

Study Timeline

• Study Start: 2019-02-12
• Study First Submitted: 2020-03-02
• Study First Submitted QC: 2020-03-02
• Study First Posted: 2020-03-04
• Primary Completion: 2024-03-27
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-14
• Last Update Posted: 2024-11-18
• Study Completion: 2026-03-27

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Histologically confirmed stage IV colon cancer (American Joint Committee on Cancer [AJCC] 7th edition) that has progressed after standard therapy that included fluorouracil (5-FU), irinotecan, oxaliplatin, bevacizumab (unless contraindicated) and an anti-EGFR antibody, if RAS wild type. Patients who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate
• Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen
• Progression of disease must be documented on the most recent scan
• Presence of measurable disease
• RAS mutation and mismatch repair deficiency (MMR) status must be determined (or tissue availability for testing if not already determined)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Life expectancy of at least 3 months
• Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
• Hemoglobin >= 9 g/dL
• Platelets (PLT) >= 75 x 10^9/L
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)
• Adequate contraception if applicable
• Women who are nursing and discontinue nursing prior to enrollment in the program
• Ability to take oral medication (i.e., no feeding tube)
• Patient able and willing to comply with study procedures as per protocol
• Patient able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures

Read More

Exclusion Criteria

• Patients who have previously received TAS-102
• Grade 2 or higher peripheral neuropathy (functional impairment)
• Symptomatic central nervous system (CNS) metastases requiring treatment
• Other active malignancy within the last 3 years (except for non-melanoma skin cancer or a non-invasive/in situ cancer)
• Pregnancy or breast feeding
• Current therapy with other investigational agents
• Active infection with body temperature >= 38 degree Celsius (C) due to infection
• Major surgery within prior 4 weeks (the surgical incision should be fully healed prior to drug administration)
• Any anticancer therapy within prior 3 weeks of first dose of study drug
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102
• Current therapy with other investigational agents or participation in another clinical study or any investigational agent received within prior 4 weeks
• Grade 3 or higher hypersensitivity reaction to oxaliplatin, or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with pre-medication
• Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse (CTCAE) grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (TAS-102, oxaliplatin)	Oxaliplatin	Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Treatment (TAS-102, oxaliplatin)	Trifluridine and Tipiracil Hydrochloride	Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Overall response rate	Up to 2 years	Response rate is defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR) by investigator assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Response rate will be calculated by dose level. Descriptive statistics will be used to analyze efficacy data using historical data as reference.

Secondary Outcome Measures

Name	Time	Method
Progression free survival	From the date of start of treatment to the date of first documented progression or any cause of death during the study, assessed up to 2 years	Progression will be assessed by a computed tomography CT scan according to RECIST criteria version 1.1. This criterion will be estimated by the Kaplan-Meier method. Patients who have not progressed or died at the time of analysis will be censored at the time of their latest follow-up with clinically stable disease.
Overall survival	Up to 2 years
Disease control rate	Up to 2 years
Duration of response	Up to 2 years	Response rate will be calculated by dose level. Descriptive statistics will be used to analyze efficacy data using historical data as reference.
Incidence of adverse events	Up to 28 days post treatment	All recorded adverse events will be listed and tabulated by system organ class and dose level. Will utilize the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) version 5.0 for toxicity and adverse event reporting.

Trial Locations

Locations (6)

Saint Barnabas Medical Center; 🇺🇸 Livingston, New Jersey, United States

RWJBarnabas Health - Monmouth Medical Center Southern Campus; 🇺🇸 Lakewood, New Jersey, United States

Trinitas Hospital and Comprehensive Cancer Center; 🇺🇸 Elizabeth, New Jersey, United States

RWJBarnabas Health - Monmouth Medical Center; 🇺🇸 Long Branch, New Jersey, United States

Rutgers Cancer Institute of New Jersey; 🇺🇸 New Brunswick, New Jersey, United States

RWJBarnabas Health - Community Medical Center; 🇺🇸 Toms River, New Jersey, United States